Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P41
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -0.49% |
| Q3 2025 | 5.52% |
| Q2 2025 | -4.57% |
| Q1 2025 | 1.78% |
| Q4 2024 | 4.83% |
| Q3 2024 | -11.63% |
| Q2 2024 | 29.57% |
| Q1 2024 | 8.00% |
| Q4 2023 | -6.39% |
| Q3 2023 | 0.24% |
| Q2 2023 | 21.79% |
| Q1 2023 | -4.53% |
| Q4 2022 | 9.89% |
| Q3 2022 | -3.68% |
| Q2 2022 | -1.23% |
| Q1 2022 | 10.27% |
| Q4 2021 | 3.40% |
| Q3 2021 | -21.48% |
| Q2 2021 | 9.87% |
| Q1 2021 | -18.05% |
| Q4 2020 | 11.89% |
| Q3 2020 | 37.08% |
| Q2 2020 | 49.49% |
| Q1 2020 | 121.68% |
| Q4 2019 | 26.60% |
| Q3 2019 | 3.13% |
| Q2 2019 | 114641.04% |
| Q1 2019 | -99.98% |
| Q4 2018 | -3.14% |
| Q3 2018 | -0.36% |
| Q2 2018 | 2.51% |
| Q1 2018 | 33.59% |
| Q4 2017 | -21.50% |
| Q3 2017 | 3.62% |
| Q2 2017 | -16.16% |
| Q1 2017 | 12.13% |
| Q4 2016 | -33.75% |
| Q3 2016 | -1.41% |
| Q2 2016 | -8.60% |
| Q1 2016 | -3.25% |